220 related articles for article (PubMed ID: 1347907)
1. The effects on survival of early treatment of human immunodeficiency virus infection.
Graham NM; Zeger SL; Park LP; Vermund SH; Detels R; Rinaldo CR; Phair JP
N Engl J Med; 1992 Apr; 326(16):1037-42. PubMed ID: 1347907
[TBL] [Abstract][Full Text] [Related]
2. Pneumocystis prophylaxis and survival in patients with advanced human immunodeficiency virus infection treated with zidovudine. The Zidovudine Epidemiology Group.
Chaisson RE; Keruly J; Richman DD; Moore RD
Arch Intern Med; 1992 Oct; 152(10):2009-13. PubMed ID: 1417373
[TBL] [Abstract][Full Text] [Related]
3. Clinical manifestations of AIDS in the era of pneumocystis prophylaxis. Multicenter AIDS Cohort Study.
Hoover DR; Saah AJ; Bacellar H; Phair J; Detels R; Anderson R; Kaslow RA
N Engl J Med; 1993 Dec; 329(26):1922-6. PubMed ID: 7902536
[TBL] [Abstract][Full Text] [Related]
4. Zidovudine in persons with asymptomatic HIV infection and CD4+ cell counts greater than 400 per cubic millimeter. The European-Australian Collaborative Group.
Cooper DA; Gatell JM; Kroon S; Clumeck N; Millard J; Goebel FD; Bruun JN; Stingl G; Melville RL; González-Lahoz J
N Engl J Med; 1993 Jul; 329(5):297-303. PubMed ID: 8100611
[TBL] [Abstract][Full Text] [Related]
5. A controlled trial of early versus late treatment with zidovudine in symptomatic human immunodeficiency virus infection. Results of the Veterans Affairs Cooperative Study.
Hamilton JD; Hartigan PM; Simberkoff MS; Day PL; Diamond GR; Dickinson GM; Drusano GL; Egorin MJ; George WL; Gordin FM
N Engl J Med; 1992 Feb; 326(7):437-43. PubMed ID: 1346337
[TBL] [Abstract][Full Text] [Related]
6. Benefit of primary prophylaxis before 18 months of age in reducing the incidence of Pneumocystis carinii pneumonia and early death in a cohort of 112 human immunodeficiency virus-infected infants. New York City Perinatal HIV Transmission Collaborative Study Group.
Thea DM; Lambert G; Weedon J; Matheson PB; Abrams EJ; Bamji M; Straus WL; Thomas PA; Krasinski K; Heagarty M
Pediatrics; 1996 Jan; 97(1):59-64. PubMed ID: 8545225
[TBL] [Abstract][Full Text] [Related]
7. Clinical manifestations and predictors of disease progression in drug users with human immunodeficiency virus infection.
Selwyn PA; Alcabes P; Hartel D; Buono D; Schoenbaum EE; Klein RS; Davenny K; Friedland GH
N Engl J Med; 1992 Dec; 327(24):1697-703. PubMed ID: 1359411
[TBL] [Abstract][Full Text] [Related]
8. Zidovudine in asymptomatic human immunodeficiency virus infection. A controlled trial in persons with fewer than 500 CD4-positive cells per cubic millimeter. The AIDS Clinical Trials Group of the National Institute of Allergy and Infectious Diseases.
Volberding PA; Lagakos SW; Koch MA; Pettinelli C; Myers MW; Booth DK; Balfour HH; Reichman RC; Bartlett JA; Hirsch MS
N Engl J Med; 1990 Apr; 322(14):941-9. PubMed ID: 1969115
[TBL] [Abstract][Full Text] [Related]
9. The risk of Pneumocystis carinii pneumonia among men infected with human immunodeficiency virus type 1. Multicenter AIDS Cohort Study Group.
Phair J; Muñoz A; Detels R; Kaslow R; Rinaldo C; Saah A
N Engl J Med; 1990 Jan; 322(3):161-5. PubMed ID: 1967190
[TBL] [Abstract][Full Text] [Related]
10. Discontinuation of secondary prophylaxis against Pneumocystis carinii pneumonia in patients with HIV infection who have a response to antiretroviral therapy. Eight European Study Groups.
Ledergerber B; Mocroft A; Reiss P; Furrer H; Kirk O; Bickel M; Uberti-Foppa C; Pradier C; D'Arminio Monforte A; Schneider MM; Lundgren JD;
N Engl J Med; 2001 Jan; 344(3):168-74. PubMed ID: 11188837
[TBL] [Abstract][Full Text] [Related]
11. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team.
Hammer SM; Squires KE; Hughes MD; Grimes JM; Demeter LM; Currier JS; Eron JJ; Feinberg JE; Balfour HH; Deyton LR; Chodakewitz JA; Fischl MA
N Engl J Med; 1997 Sep; 337(11):725-33. PubMed ID: 9287227
[TBL] [Abstract][Full Text] [Related]
12. A controlled trial of intravenous immune globulin for the prevention of serious bacterial infections in children receiving zidovudine for advanced human immunodeficiency virus infection. Pediatric AIDS Clinical Trials Group.
Spector SA; Gelber RD; McGrath N; Wara D; Barzilai A; Abrams E; Bryson YJ; Dankner WM; Livingston RA; Connor EM
N Engl J Med; 1994 Nov; 331(18):1181-7. PubMed ID: 7935655
[TBL] [Abstract][Full Text] [Related]
13. Race, sex, drug use, and progression of human immunodeficiency virus disease.
Chaisson RE; Keruly JC; Moore RD
N Engl J Med; 1995 Sep; 333(12):751-6. PubMed ID: 7643881
[TBL] [Abstract][Full Text] [Related]
14. Logarithmic relationship of the CD4 count to survival in patients with human immunodeficiency virus infection.
Nightingale SD; Jockusch JD; Haslund I; Cal SX; Peterson DM; Loss SD
Arch Intern Med; 1993 Jun; 153(11):1313-8. PubMed ID: 8099477
[TBL] [Abstract][Full Text] [Related]
15. A comparison of immediate with deferred zidovudine therapy for asymptomatic HIV-infected adults with CD4 cell counts of 500 or more per cubic millimeter. AIDS Clinical Trials Group.
Volberding PA; Lagakos SW; Grimes JM; Stein DS; Rooney J; Meng TC; Fischl MA; Collier AC; Phair JP; Hirsch MS
N Engl J Med; 1995 Aug; 333(7):401-7. PubMed ID: 7616988
[TBL] [Abstract][Full Text] [Related]
16. [Impact of zidovudine treatment and the pneumocystis carinii prophylaxis in natural history of patients with HIV infection].
Sáiz Hervas E; Castilla Castellano V; Miquel Plaza J; Benito Blanco AM; Martín Llorens MM; Pastor de Blas M; Izquierdo P; Muñoz Jareño MA; Sierra A; Nieto MA; Moreno Collado AM; Fraguas C
An Med Interna; 1998 Mar; 15(3):132-7. PubMed ID: 9580410
[TBL] [Abstract][Full Text] [Related]
17. A controlled trial of trimethoprim-sulfamethoxazole or aerosolized pentamidine for secondary prophylaxis of Pneumocystis carinii pneumonia in patients with the acquired immunodeficiency syndrome. AIDS Clinical Trials Group Protocol 021.
Hardy WD; Feinberg J; Finkelstein DM; Power ME; He W; Kaczka C; Frame PT; Holmes M; Waskin H; Fass RJ
N Engl J Med; 1992 Dec; 327(26):1842-8. PubMed ID: 1448121
[TBL] [Abstract][Full Text] [Related]
18. Duration of the survival benefit of zidovudine therapy in HIV infection.
Moore RD; Keruly JC; Chaisson RE
Arch Intern Med; 1996 May; 156(10):1073-7. PubMed ID: 8638994
[TBL] [Abstract][Full Text] [Related]
19. Zidovudine, didanosine, or both as the initial treatment for symptomatic HIV-infected children. AIDS Clinical Trials Group (ACTG) Study 152 Team.
Englund JA; Baker CJ; Raskino C; McKinney RE; Petrie B; Fowler MG; Pearson D; Gershon A; McSherry GD; Abrams EJ; Schliozberg J; Sullivan JL
N Engl J Med; 1997 Jun; 336(24):1704-12. PubMed ID: 9182213
[TBL] [Abstract][Full Text] [Related]
20. A randomized trial of the discontinuation of primary and secondary prophylaxis against Pneumocystis carinii pneumonia after highly active antiretroviral therapy in patients with HIV infection. Grupo de Estudio del SIDA 04/98.
Lopez Bernaldo de Quiros JC; Miro JM; Peña JM; Podzamczer D; Alberdi JC; Martínez E; Cosin J; Claramonte X; Gonzalez J; Domingo P; Casado JL; Ribera E;
N Engl J Med; 2001 Jan; 344(3):159-67. PubMed ID: 11172138
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
